153 related articles for article (PubMed ID: 34400460)
1. Unmet needs in non-metastatic castration-resistant prostate cancer from the Japanese patient perspective: a discrete choice experiment.
Uemura H; Matsushima H; Yokomizo A; Kobayashi K; Arai G; Satoh T; Grillo V; Chen Y; Singh S; Ledesma DA
BMJ Open; 2021 Aug; 11(8):e052471. PubMed ID: 34400460
[TBL] [Abstract][Full Text] [Related]
2. Understanding Treatment Strategies and Preferences in Nonmetastatic Castration-Resistant Prostate Cancer From the Japanese Physician Perspective.
Suzuki K; Grillo V; Chen Y; Singh S; Ledesma DA
JCO Glob Oncol; 2021 Feb; 7():302-310. PubMed ID: 33617305
[TBL] [Abstract][Full Text] [Related]
3. Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment.
Uemura H; Matsubara N; Kimura G; Yamaguchi A; Ledesma DA; DiBonaventura M; Mohamed AF; Basurto E; McKinnon I; Wang E; Concialdi K; Narimatsu A; Aitoku Y
BMC Urol; 2016 Nov; 16(1):63. PubMed ID: 27814714
[TBL] [Abstract][Full Text] [Related]
4. Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment.
Srinivas S; Mohamed AF; Appukkuttan S; Botteman M; Ng X; Joshi N; Tsai JH; Fang J; Waldeck AR; Simmons SJ
Cancer Med; 2020 Sep; 9(18):6586-6596. PubMed ID: 32725755
[TBL] [Abstract][Full Text] [Related]
5. Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation.
Rentz AM; Mansukhani SG; Liu J; Lloyd AJ; Heidenreich S; Matza LS; Dawson NA; Shore N; Freedland SJ
Urol Oncol; 2021 Jun; 39(6):367.e7-367.e17. PubMed ID: 33736976
[TBL] [Abstract][Full Text] [Related]
6. Physician preferences for non-metastatic castration-resistant prostate cancer treatment.
Srinivas S; Mohamed AF; Appukkuttan S; Botteman M; Ng X; Joshi N; Horodniceanu E; Waldeck AR; Simmons SJ
BMC Urol; 2020 Jun; 20(1):73. PubMed ID: 32571276
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
[TBL] [Abstract][Full Text] [Related]
8. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer.
Mori K; Kimura T; Fukuokaya W; Iwatani K; Sakanaka K; Kurokawa G; Yanagisawa T; Sasaki H; Miki J; Shimomura T; Miki K; Hatano T; Endo K; Egawa S
Int J Clin Oncol; 2020 Mar; 25(3):479-485. PubMed ID: 31512007
[TBL] [Abstract][Full Text] [Related]
9. Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment.
Eliasson L; de Freitas HM; Dearden L; Calimlim B; Lloyd AJ
Clin Ther; 2017 Apr; 39(4):723-737. PubMed ID: 28366592
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
11. Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey.
George DJ; Mohamed AF; Tsai JH; Karimi M; Ning N; Jayade S; Botteman M
Cancer Med; 2023 Mar; 12(5):6040-6055. PubMed ID: 36226867
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer.
Hird AE; Magee DE; Bhindi B; Ye XY; Chandrasekar T; Goldberg H; Klotz L; Fleshner N; Satkunasivam R; Klaassen Z; Wallis CJD
Clin Genitourin Cancer; 2020 Oct; 18(5):343-350. PubMed ID: 32278840
[TBL] [Abstract][Full Text] [Related]
13. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Lefebvre P; McQuarrie K; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2020 Jan; 37(1):512-526. PubMed ID: 31813087
[TBL] [Abstract][Full Text] [Related]
14. Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials.
Terrisse S; Karamouza E; Parker CC; Sartor AO; James ND; Pirrie S; Collette L; Tombal BF; Chahoud J; Smeland S; Erikstein B; Pignon JP; Fizazi K; Le Teuff G;
JAMA Oncol; 2020 Feb; 6(2):206-216. PubMed ID: 31830233
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer.
Morgans AK; Shore N; Cope D; McNatty A; Moslehi J; Gomella L; Sartor O
Urol Oncol; 2021 Jan; 39(1):52-62. PubMed ID: 32958445
[TBL] [Abstract][Full Text] [Related]
16. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
Wu B; Li SS; Song J; Pericone CD; Behl AS; Dawson NA
J Med Econ; 2020 Jan; 23(1):54-63. PubMed ID: 31589086
[No Abstract] [Full Text] [Related]
17. Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan.
Nakayama M; Kobayashi H; Okazaki M; Imanaka K; Yoshizawa K; Mahlich J
Am J Mens Health; 2018 Jul; 12(4):1094-1101. PubMed ID: 29774804
[TBL] [Abstract][Full Text] [Related]
18. Conceptual assessment of HRQOL among Japanese non-metastatic castration-resistant prostate cancer (nmCRPC) patients.
Nishimura K; Shiota M; Eto M; Satoh T; Stroupe A; Seo C; Uzumcu A; Ledesma DA
Cancer Med; 2023 Jan; 12(2):1762-1778. PubMed ID: 35770744
[TBL] [Abstract][Full Text] [Related]
19. Physician preferences for nonmetastatic castration-resistant prostate cancer treatment in China.
Fan Y; Guo X; Campobasso D; He Z
Front Oncol; 2024; 14():1382678. PubMed ID: 38835395
[TBL] [Abstract][Full Text] [Related]
20. Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.
Fizazi K; Massard C; Bono P; Kataja V; James N; Tammela TL; Joensuu H; Aspegren J; Mustonen M
Eur Urol Focus; 2017 Dec; 3(6):606-614. PubMed ID: 28753849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
